Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Once-Daily vs Twice-Daily Apremilast in Healthy Volunteers
NCT02777554Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in psoriasis and psoriatic arthritis (PsA) (6 arms), sponsored by Amgen. Primary endpoints: Peak Maximum Plasma Concentration at Day 1, Area Under the Concentration-time Curve From Time Zero to 24 Hours and 2 more. Started Aug 2016; status: completed.
02
Drugs
apremilast
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02777554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777554.